BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRX
BioCryst Pharmaceuticals — Q3 2020 Earnings Presentation
14 slides from BioCryst Pharmaceuticals's earnings presentation, Nov 5, 2020
Slide 1: Third Quarter 2020 Results Call
Third Quarter 2020 Results Call Corporate Update & Financial Results November 5, 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain
Slide 3: Agenda
Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ ORLADEYO™ (berotralstat) Launch Readiness: Charlie Gayer – Chief Commercial Officer Megan Sniecinski – Chief Business Officer ◆ BCX9930 Update Dr. Bill Sheridan – Chief Medical Officer ◆ Financial Update Anthony Doyl
Slide 4: Corporate Update
Corporate Update: Jon Stonehouse President and Chief Executive Officer 4
Slide 5: Multiple Upcoming Program Updates
Multiple Upcoming Program Updates Q42020 PDUFA Q12021 Q22021 Dec. 3, 2020 Data from part 1 ORLADEYO Approval decision Phase 1 data from Data from completed Approval decision galidesivir COVID-19 trial approval in U.S. on ORLADEYO BCX9250 trial in FOP BCX9930 dose ranging on ORLADEYO in EU (Q4 2020)
Slide 6: ORLADEYO Launch Readiness
ORLADEYO™ (berotralstat) Launch Readiness: Charlie Gayer – Chief Commercial Officer Megan Sniecinski – Chief Business Officer 6
Slide 7: Coming Soon: Orladeyo
Coming Soon: Orladeyo™ diggeryst COMING SOON O rl a d eyo orladeyo (berotralstat) 150 mg capsule (berotralstat) 150 mg capsule
Slide 8: Recent and Upcoming Publications Support Launch
Recent and Upcoming Publications Support Launch APeX-2 Trial American College of Allergy, Asthma & Immunology (ACAAI) 2020 Annual Scientific Meeting November 13-15, 2020 Distinguished Industry Oral Abstract: • Berotralstat Reduces Attacks in Patients with Hereditary Angioedema (HAE): APeX-2 Trial 48
Slide 9: Clinical Update
Clinical Update: Dr. Bill Sheridan – Chief Medical Officer 9
Slide 10: Factor D: An Outstanding Drug Target for Complement-mediated Diseases
Factor D: An Outstanding Drug Target for Complement-mediated Diseases •Factor D is essential to initiate the Alternative Pathway •Blocking Factor D blocks the Alternative Pathway and all downstream products Spectrum of Alternative Pathway Dysregulation Diseases Factor D BCX9930 Hematology Rheumatolo
Slide 11: Oral Monotherapy with BCX9930 Controls IVH and EVH Hemolysis
Oral Monotherapy with BCX9930 Offers Advantage of Controlling Both Intravascular (IVH) and Extravascular (EVH) Hemolysis Goal of Total Patient Outcomes from Hemolytic Control Controlled Hemolysis over Time Relieve Anemia IVH Control Hemoglobin LDH Hemolytic Control RBC/Granulocyte Reduce PNH Clinica
Slide 12: Financial Update
Financial Update: Anthony Doyle– Chief Financial Officer 12
Slide 13: Cash position & 2020 guidance
Cash position & 2020 guidance (in millions) Cash, cash equivalents, restricted cash & investments at December 31, 2019 $138 Cash, cash equivalents, restricted cash & investments at September 30, 2020 $149 Senior credit facility A $46 REVISED FY 2020 GUIDANCE Net operating cash utilization $150-165 O
Slide 14: Thank You… Questions and Answers
Thank You… Questions and Answers
BioCryst Pharmaceuticals — Q3 2020 Earnings Presentation on 6ix